C2N Diagnostics LLC (C2N Diagnostics) is a protein diagnostic and therapeutic discovery company that offers progressive neurodegeneration solutions. The company develops tools and assays for clinical drug development, preclinical drug discovery and early detection and assessment of neurodegenerative disorders. It offers products such as SILK-Ab and SISAQ-Ab assays. C2N Diagnostics' products are used for the measurement of kinetics, or in vivo metabolism, and absolute quantitation of brain derived proteins. The company also develops products used in the treatment of Huntington’s disease, Parkinson's disease, brain injury, amyotrophic lateral sclerosis and schizophrenia, among others. C2N Diagnostics is headquartered in St. Louis, Missouri, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company C2N Diagnostics LLC
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- C2N Diagnostics LLC Company Overview
- C2N Diagnostics LLC Company Snapshot
- C2N Diagnostics LLC Pipeline Products and Ongoing Clinical Trials Overview
- C2N Diagnostics LLC - Pipeline Analysis Overview
- C2N Diagnostics LLC - Key Facts
- C2N Diagnostics LLC - Major Products and Services
- C2N Diagnostics LLC Pipeline Products by Development Stage
- C2N Diagnostics LLC Ongoing Clinical Trials by Trial Status
- C2N Diagnostics LLC Pipeline Products Overview
- Diagnostic Test - Alzheimer's Disease
- Diagnostic Test - Alzheimer's Disease Product Overview
- Diagnostic Test - Brain Disease
- Diagnostic Test - Brain Disease Product Overview
- Diagnostic Test - Neurological Disease
- Diagnostic Test - Neurological Disease Product Overview
- Multi-Analyte Combination Assay
- Multi-Analyte Combination Assay Product Overview
- p-tau217 Blood Test
- p-tau217 Blood Test Product Overview
- p-tau217 Blood Test Clinical Trial
- PrecivityAD2 Blood Test
- PrecivityAD2 Blood Test Product Overview
- PrecivityAD2 Blood Test Clinical Trial
- C2N Diagnostics LLC - Key Competitors
- C2N Diagnostics LLC - Key Employees
- C2N Diagnostics LLC - Locations And Subsidiaries
- Head Office
- Recent Developments
- C2N Diagnostics LLC, Recent Developments
- Feb 24, 2025: C2N Diagnostics’ PrecivityAD2 Blood Test Receives MHRA Medical Device Certification in the United Kingdom
- Jan 31, 2025: Study Highlights How C2N’s PrecivityAD2 Blood Biomarker Test Use Improves Clinical Decision-Making in the Evaluation for Alzheimer’s Disease
- Jan 28, 2025: First Canadian Clinic To Offer c2n’s PRECIVITYAD2 Blood Test To Help Healthcare Providers Diagnose Alzheimer’s Disease, Joining Global Community in Embracing Breakthrough Technology
- Jan 15, 2025: C2N Diagnostics Partners with The Michael J. Fox Foundation to Uncover New Links Between Parkinson’s Disease, Lewy Body Dementia and Alzheimer’s Disease
- Nov 14, 2024: New Investment from the Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator (DxA) Leads Efforts to Develop Standardization Materials for Leading Diagnostic Biomarker
- Sep 30, 2024: C2N Diagnostics Receives $15 Million Program Related Investment from GHR Foundation to Develop Tau Tangle Pathology Test for Diagnosing, Staging Alzheimer’s Disease
- Sep 25, 2024: Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator (DxA) Invests More Than $7 Million in C2N Diagnostics' Blood Tests
- Sep 25, 2024: C2N Receives Funding from Diagnostics Accelerator to Develop a Decentralized Clinical Mass Spectrometry Solution to Enable High-Performance Alzheimer’s Disease Testing Worldwide
- Aug 23, 2024: Multiple Sclerosis Appears to Protect Against Alzheimer’s Disease
- Aug 09, 2024: C2N signs deal with Unilabs to expand access for Alzheimer’s blood tests
- Appendix
- Methodology
- About the Analyst
- Contact the Publisher
- Disclaimer
- C2N Diagnostics LLC Pipeline Products and Ongoing Clinical Trials Overview
- C2N Diagnostics LLC Pipeline Products by Indication
- C2N Diagnostics LLC Ongoing Clinical Trials by Trial Status
- C2N Diagnostics LLC, Key Facts
- C2N Diagnostics LLC, Major Products and Services
- C2N Diagnostics LLC Number of Pipeline Products by Development Stage
- C2N Diagnostics LLC Pipeline Products Summary by Development Stage
- C2N Diagnostics LLC Ongoing Clinical Trials by Trial Status
- C2N Diagnostics LLC Ongoing Clinical Trials Summary
- Diagnostic Test - Alzheimer's Disease - Product Status
- Diagnostic Test - Alzheimer's Disease - Product Description
- Diagnostic Test - Brain Disease - Product Status
- Diagnostic Test - Brain Disease - Product Description
- Diagnostic Test - Neurological Disease - Product Status
- Diagnostic Test - Neurological Disease - Product Description
- Multi-Analyte Combination Assay - Product Status
- Multi-Analyte Combination Assay - Product Description
- p-tau217 Blood Test - Product Status
- p-tau217 Blood Test - Product Description
- p-tau217 Blood Test - The Swedish BioFINDER - Memory Clinic Study
- p-tau217 Blood Test - The Swedish Biofinder 2 Study
- PrecivityAD2 Blood Test - Product Status
- PrecivityAD2 Blood Test - Product Description
- PrecivityAD2 Blood Test - Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
- PrecivityAD2 Blood Test - The Swedish BioFINDER Study: Early Diagnosis of Alzheimer's Disease - a Multidisciplinary Approach
- C2N Diagnostics LLC, Key Employees
- Glossary
- C2N Diagnostics LLC Pipeline Products by Equipment Type
- C2N Diagnostics LLC Pipeline Products by Development Stage
- C2N Diagnostics LLC Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Galbraith Laboratories Inc
- Applied BioPhysics Inc
- CD Diagnostics Inc
